The evolution of mild parkinsonian signs in aging by Mahoney, Jeannette et al.
ORIGINAL COMMUNICATION
The evolution of mild parkinsonian signs in aging
Jeannette R. Mahoney • Joe Verghese •
Roee Holtzer • Gilles Allali
Received: 9 June 2014 / Revised: 11 July 2014 / Accepted: 12 July 2014 / Published online: 22 July 2014
 Springer-Verlag Berlin Heidelberg 2014
Abstract The progression of mild parkinsonian signs in
the absence of idiopathic Parkinson’s disease in aging is
unclear. This study aims to identify predictors of the evo-
lution of mild parkinsonian signs in non-demented older
adults. Two hundred ten participants (76.25 ± 7.10 years,
57 % women) were assessed at baseline and 1-year follow-up.
Mild parkinsonian signs were defined as the presence of
bradykinesia, rigidity and/or rest tremor. Depending upon
the presence of these features at baseline and follow-up,
participants were divided into one of four groups (no,
transient, persistent or new-onset mild parkinsonian
signs). Physical function was assessed using gait velocity.
Ninety-five participants presented with mild parkinso-
nian signs at baseline. At 1-year follow-up, 59 demon-
strated persistent mild parkinsonian signs, while 36
recovered (i.e., transient). Participants with persistent mild
parkinsonian signs were older (79.66 ± 7.15 vs. 75.81 ± 7.37
years, p = 0.01) and evidenced slower gait velocity
(90.41 ± 21.46 vs. 109.92 ± 24.32 cm/s, p \ 0.01) com-
pared to those with transient mild parkinsonian signs. Gait
velocity predicted persistence of mild parkinsonian signs,
even after adjustments (OR: 0.96, 95 % CI: 0.94–0.98).
Fifty-five participants demonstrated new-onset of mild
parkinsonian signs. In comparison to participants without
mild parkinsonian signs, presence of cardiovascular but not
cerebrovascular disease at baseline was associated with
new-onset mild parkinsonian signs. Our study reveals that
gait velocity was the main predictor of persistent mild
parkinsonian signs, whereas cardiovascular disease was
associated with new-onset mild parkinsonian signs. These
findings suggest a vascular mechanism for the onset of
mild parkinsonian signs and a different mechanism, pos-
sibly neurodegenerative, for the persistence of mild par-
kinsonian signs.
Keywords Mild parkinsonian signs  Aging  Gait 
Cardiovascular disease  Cerebrovascular disease
Introduction
Mild parkinsonian signs (MPS) are common in aging
even in the absence of idiopathic Parkinson’s disease
(PD), with a wide variance in prevalence ranging from 15
to 52 % [1, 2]. Age, criteria employed to define MPS, and
cognitive status likely explain the large discrepancy in
reported prevalence rates. In previous studies, MPS were
associated not only with vascular risk factors [3],
depression [4], dementia [5–7], and mortality [1, 8, 9], but
also with functional disability [10, 11]. Among functional
disability, the use of walking aids was associated with
MPS [2].
While previous longitudinal studies have established the
relationship of MPS with incident dementia in aging [6, 7,
12, 13], their association with other important clinical
outcomes like gait disorders or cardiovascular conditions
has not been documented. Recently cerebrovascular lesions,
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including macro and microinfarcts, were associated with
MPS and with parkinsonian gait [14]. Besides vascular
lesions and dementia, a pathological study of 744 deceased
participants with antemortem MPS assessment demon-
strated that nigral neuronal loss, but not nigral Lewy bodies
deposition was associated with MPS [15]. However, to our
knowledge no study to date has identified risk factors
associated with the progression of MPS in aging.
To address this knowledge gap, we conducted a pro-
spective cohort study investigating predictors of MPS in
community residing non-demented older adults without PD
or other parkinsonian syndromes assessed at baseline and at
1-year follow-up. We hypothesized that vascular patho-
physiological mechanisms would be associated with the
presence of MPS in the elderly, but the contribution of
additional factors related with neurodegenerative pro-
cesses, would be more likely in older adults with persistent
MPS at follow-up.
Methods
Participants
Four hundred thirty-nine non-demented adults aged 65 and
older were recruited in an ongoing cohort study entitled
Central Control of Mobility in Aging (CCMA) from June
2011 to November 2013, and of whom 264 completed a
1-year follow up. The CCMA longitudinal study aims to
determine cognitive and brain predictors of mobility
decline and disability in aging. The study procedure has
been previously described [16, 17]. Briefly, participants
enrolled in the CCMA study are non-demented older
adults residing in lower Westchester County who have
successfully passed a telephone-screening interview. Par-
ticipants engage in two in-house evaluations per year,
where they receive comprehensive neurological, neuro-
psychological, and physical examinations. Consensus
diagnostic case conferences were conducted to assure that
participants did not meet criteria for dementia [18]. Of the
264 participants who completed the 1-year follow-up
evaluation, participants without complete neurological
examinations (n = 37), idiopathic PD at baseline (n = 7),
missing quantitative gait assessments at baseline (n = 6),
or prescribed dopamine-blocking agents/neuroleptics
(n = 4) were excluded from this analysis. Following
exclusions, 210 non-demented older adults were included
in the current analysis (mean age: 76.25 ± 7.10 years,
57 % women). The institutional review board of the Albert
Einstein College of Medicine approved the experimental
procedures and all participants provided written informed
consent in accordance with the tenets of the Declaration of
Helsinki.
Mild parkinsonian signs and clinical assessment
Comprehensive neurological examination included assess-
ment for clinical gait abnormalities [19], MPS, and medical
illnesses. MPS were systematically ascertained in partici-
pants by the clinician using the motor evaluation portion
(Part III) of the original version of the Unified Parkinson’s
Disease Rating Scale (UPDRS) [20]. Severity indices for
individual MPS were calculated by summing clinician
ratings (0–4) within 3 core domains: (1) bradykinesia in
extremities and body (UPDRS#23-26, 31); (2) rigidity in
extremities and neck (UPDRS#22); and (3) rest tremor in
extremities (UPDRS#20). A total MPS score was subse-
quently created, both at baseline and at follow-up, by
adding the severity indices of the individual MPS. As in
our previous work, we aimed to identify early markers of
abnormal motor aging by taking a sensitive approach to
define MPS based on the presence of any one feature of
MPS [21], but more stringent methods have previously
been employed [7, 10]. For the MPS severity score, the
Cronbach’s a of 0.85 indicated good internal consistency,
with excellent internal consistency for bradykinesia (0.90)
and tremor (0.90), and good internal consistency for
rigidity (0.88). The inter-rater reliability of MPS across the
two clinicians revealed good inter-rater reliability (kappa,
0.60–0.90).
Of the 210 participants, 95 had MPS and 115 had no
MPS at baseline. We examined the evolution of MPS in
this cohort, by dividing participants with MPS at baseline
(e.g., MPS?) into two groups: (i) MPS at baseline and at
1-year follow-up (persistent MPS group) and (ii) MPS at
baseline but not at 1-year follow-up (transient MPS group).
Further, to investigate potential contributors to MPS
development, we divided participants without MPS at
baseline (e.g., MPS-) into two groups: (iii) no MPS at
baseline and at 1-year follow-up (absent MPS group) and
(iv) no MPS at baseline and onset of new MPS at 1-year
follow-up (new onset MPS group; Fig. 1).
The clinician documented the presence of depression,
medical illnesses, cardiovascular disease, cerebrovascular
disease, and cardiovascular risk factors, as these have been
previously associated with MPS [22]. The geriatric
depression scale (GDS [23]) was used to measure depres-
sion. Global health status summary scores (range 0–10)
were obtained from dichotomous rating of diabetes,
chronic heart failure, arthritis, hypertension, depression,
stroke, Parkinson’s disease, chronic obstructive pulmonary
disease, angina, and myocardial infarction [24, 25]. History
of vascular diseases and medical illnesses were obtained
through clinical interview. Vascular diseases were cate-
gorized as vascular risk factors (any one of diabetes,
hypertension, hypercholesterolemia, BMI [ 30, and
smoking), cardiovascular disease (any one of myocardial
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infarction, angina, arrhythmia, and chronic heart failure),
and cerebrovascular disease (any one of stroke or transient
ischemic attacks). Vascular severity scores were also cal-
culated by summing the presence of conditions within each
of the three vascular domains.
Physical and cognitive function
Quantitative gait assessments were conducted by a research
assistant (blinded to the MPS status) as described in our
previous studies [24, 26, 27]. Gait velocity (cm/s) was
measured using an instrumented walkway with embedded
pressure sensors (GAITRite, CIR Systems, Havertown,
PA). The GAITRite system is widely used in clinical and
research settings and has excellent psychometric proper-
ties. For the purposes of this study, we only report gait
velocity because it can be measured ubiquitously with a
stopwatch over a fixed distance and does not require the
use of instrumented methods.
Global cognitive status was assessed using Repeatable
Battery for Assessment of Neuropsychological Status
(RBANS) total score. The RBANS, a brief cognitive test
with alternate forms, measures immediate and delayed
memory, attention, language, and visuo-spatial abilities,
which also provides a total index score [28].
Statistics
Descriptive statistics (mean and SD) were calculated for all
four MPS groups. Data were inspected descriptively and
graphically and the normality of model assumptions was
formally tested. Separate analyses were conducted for
individuals with and without MPS at baseline. That is,
within the MPS- group, individuals who never demon-
strated MPS (e.g., absent group) were compared to those
who developed MPS at follow-up (e.g., new onset MPS
group). Similarly, within the MPS? group, those that
continued to demonstrate MPS at 1-year follow-up (e.g.,
persistent MPS group) were compared to those who did not
demonstrate MPS at follow-up (e.g., transient MPS group).
Differences between groups were assessed using inde-
pendent t tests and Bonferroni corrections were applied to
account for multiple comparisons within each domain (e.g.,
demographics, MPS, vascular, and physical function indi-
ces, Table 1). Binary logistic regression analyses were
subsequently performed to examine the association of
persistent vs. transient MPS (independent variables) with
gait velocity, health, vascular, depression, and RBANS
total scores (dependent variables) using SPSS version 20
[29]. Unadjusted univariate regressions were conducted
first, followed by multivariate regressions adjusted for both
age and gender. Similar univariate and multivariate
regressions were also conducted for the absent vs. new
onset MPS comparison groups.
Results
Baseline characteristics of the sample are provided in
Table 1 for individuals with persistent and transient MPS
and in Table 2 for those with absent and new onset MPS.
Regardless of MPS classification, individuals were deemed
relatively healthy and cognitively intact as determined by
their global health status (GHS) and RBANS total score.
Within the MPS ? groups, rigidity was the most common
MPS at baseline, followed by bradykinesia, and rest tremor
Fig. 1 Classification of eligible
participants based on MPS
status. Flowchart of CCMA
participants based on presence
or absence of mild parkinsonian
signs at baseline and 1-year
follow-up
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(Table 1). Results from logistic regression adjusted for age
and gender revealed that the presence of bradykinesia
significantly predicted inclusion in either the transient or
persistent MPS group (OR = 0.11, p \ 0.01).
Of the 95 participants with MPS at baseline, 66 had one
MPS and 29 had two MPS. To further confirm the asso-
ciation between MPS status and gait velocity, we con-
ducted a sensitivity analysis using more stringent criteria to
determine persistent vs. transient MPS status by requiring
the presence of any two (instead of just one) features of
MPS at baseline and at follow-up to define persistence.
Participants with two features of MPS at baseline but none
or one feature of MPS at follow-up were considered in the
control group in this sensitivity analysis. Using the same
multivariate logistic regression analysis, results confirmed
that only gait velocity significantly predicts the progression
of MPS (OR = 0.97, p = 0.02), even after controlling for
age and gender. Differences in gait velocity were noted at
baseline (t = 4.09, p \ 0.001) and at follow-up (t = 4.09,
p \ 0.001) between transient and persistent MPS groups
(Fig. 2).
Regarding new onset MPS, comparisons between the
absent vs. new onset MPS groups revealed that participants
in the new onset group demonstrated significantly more
cardiovascular disease than those in the absent group
(Table 3). This significant difference in severity of
Table 1 Baseline characteristics for individuals with MPS
Persistent
(n = 59)
Transient
(n = 36)
p value
Demographics
Age (years) 79.66 (7.15) 75.81 (7.37) 0.01
Education (years) 13.95 (3.21) 15.39 (2.71) 0.03
% Female 57.00 47.00 0.32
GHS score (0–10) 1.70 (1.10) 1.75 (1.03) 0.81
GDS score (0–30) 5.54 (4.05) 3.94 (3.22) 0.04
MPS Indices
Bradykinesia
(% present)
53.00 17.00 <0.01
Rigidity (% present) 83.00 83.00 0.97
Tremor (% present) 9.00 8.00 0.98
Vascular
Vascular risk factor
(0–5)
1.89 (0.98) 1.90 (1.27) 0.97
Cardiovascular
conditions (0–4)
0.25 (0.50) 0.42 (1.25) 0.43
Cerebrovascular
conditions (0–2)
0.08 (0.28) 0.12 (0.33) 0.59
Physical and cognitive function
Gait velocity (cm/s) 90.41 (21.46) 109.92
(24.32)
<0.01
RBANS total score 90.36 (12.62) 94.19 (11.92) 0.15
MPS Mild Parkinsonian signs, GHS Global Health Score, GDS
Geriatric Depression Scale, RBANS Repeatable Battery for the
Assessment of Neuropsychological Status, p values presented in bold
survive Bonferroni correction
Table 2 Baseline characteristics for individuals without MPS
Absent
(n = 60)
New onset
(n = 55)
p value
Demographics
Age (years) 74.12 (5.88) 75.22 (6.93) 0.36
Education (years) 14.40 (2.54) 15.04 (3.48) 0.26
% Female 57.00 64.00 0.45
GHS score (0–10) 1.23 (0.93) 1.47 (1.27) 0.26
GDS score (0–30) 3.50 (2.33) 4.20 (3.36) 0.20
Vascular
Vascular risk factor
(0–5)
1.43 (1.06) 1.45 (1.12) 0.92
Cardiovascular
conditions (0–4)
0.08 (0.33) 0.27 (0.49) 0.02
Cerebrovascular
conditions (0–2)
0.03 (0.18) 0.19 (0.39) 0.21
Physical and cognitive function
Gait velocity (cm/s) 108.56
(23.22)
101.15 (23.95) 0.10
RBANS total score 90.36
(12.62)
94.19 (11.92) 0.15
MPS Mild Parkinsonian signs, GHS Global Health Score, GDS
Geriatric Depression Scale, RBANS Repeatable Battery for the
Assessment of Neuropsychological Status, p value presented in bold
survives Bonferroni correction
Fig. 2 Evolution of Gait Velocity for individuals with transient and
persistent mild parkinsonian signs. A depiction of gait velocity for the
95 individuals with transient and persistent mild parkinsonian signs at
baseline and 1-year follow up. Participants in transient group (solid
grey trace) improved their gait velocity over 1 year from 110 to
112 cm/s, whereas those in the persistent group (dashed grey trace)
decreased their gait velocity from 90 to 88 cm/s. Bars represent
standard errors of the mean
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cardiovascular disease persisted at both the univariate
(OR = 3.31, p = 0.02) and multivariate levels (OR = 3.59,
p = 0.03; Table 4).
Discussion
Our study shows that MPS is transient in 38 % of healthy
older adults, and that gait velocity predicts MPS stability.
Furthermore, the presence of cardiovascular disease, but
not gait velocity or other selected predictors, was associ-
ated with the onset of new MPS at 1-year follow-up.
The etiopathogenesis of MPS is unclear in the elderly,
and seems to be multifactorial [22]. MPS could represent
an early marker of neurodegenerative disorders like PD or
Alzheimer’s disease (AD), a signature of small vascular
infarcts [22], or a feature of neuronal loss in the
dopaminergic system as suggested by a recent neuro-
pathological study [15]. Although none of these previously
suggested causes are reversible, more than one-third of the
participants in our study did not present with any MPS at
the 1-year follow-up visit. Disappearance of MPS could be
attributed to brain plasticity in normal older adults, as the
CCMA cohort does not include participants with dementia
at baseline. Unfortunately, information on interval reha-
bilitative efforts that might influence brain recovery and
account for the disappearance of MPS in our participants
was not available. The potential reversibility of MPS is
important to consider for clinicians, because it could sug-
gest that MPS does not necessarily foreshadow an imme-
diate progressive condition.
Among the selected potential predictors of progressive
MPS, only gait velocity was associated with persistent
MPS at 1-year, even after using more stringent criteria for
Table 3 Predictors of
persistent vs. transient mild
parkinsonian signs
Univariate Multivariate
Variable Odds
ratio
95 % C.I. p value Odds
ratio
95 % C.I. p value
Lower Upper Lower Upper
Age, years 1.08 1.01 1.15 0.02 1.04 0.97 1.12 0.26
Gender (female) 1.52 0.66 3.50 0.33 1.67 0.62 4.50 0.31
GHS (0–10) 0.95 0.65 1.41 0.81 0.67 0.35 1.25 0.67
GDS (0–30) 1.13 1.00 1.29 0.06 1.11 0.96 1.28 0.16
Vascular risk factor (0–5) 1.01 0.70 1.44 0.97 1.16 0.68 2.00 0.59
Cardiovascular conditions (0–4) 1.25 0.69 2.27 0.45 1.22 0.61 2.43 0.58
Cerebrovascular conditions (0–2) 1.48 0.36 6.13 0.59 2.13 0.38 13.88 0.36
Gait velocity (cm/s) 0.96 0.94 0.98 <0.01 0.97 0.94 0.99 <0.01
Cognition (RBANS Total Score) 0.97 0.94 1.01 0.15 0.99 0.95 1.03 0.55
Table 4 Predictors of absent vs. new onset mild parkinsonian signs
Univariate Multivariate
Variable Odds ratio 95 % C.I. p value Odds ratio 95 % C.I. p value
Lower Upper Lower Upper
Age, years 1.03 0.97 1.09 0.36 0.99 0.92 1.06 0.78
Gender (female) 1.34 0.63 2.83 0.45 1.25 0.56 2.80 0.59
GHS (0–10) 1.22 0.87 1.71 0.25 1.00 0.58 1.72 1.00
GDS (0–30) 1.09 0.96 1.24 0.19 1.10 0.95 1.28 0.20
Vascular risk factor (0–5) 1.01 0.73 1.43 0.92 0.95 0.58 1.55 0.83
Cardiovascular conditions (0–4) 3.31 1.17 9.36 0.02 3.59 1.14 11.30 0.03
Cerebrovascular conditions (0–2) 2.90 0.54 15.61 0.22 2.34 0.32 16.96 0.40
Gait velocity (cm/s) 0.99 0.97 1.00 0.10 0.99 0.97 1.01 0.37
Cognition (RBANS total score) 0.98 0.95 1.02 0.35 0.99 0.95 1.02 0.43
Unadjusted univariate and multivariate regressions were performed to examine associations of MPS status (independent variables) with gait
velocity, health (GHS), depression (GDS), vascular risk factors, cardiovascular disease, cerebrovascular disease, and cognition (dependent
variables). Bold values indicate significant p values
GHS Global Health Score, GDS Geriatric Depression Scale, RBANS Repeatable Battery for the Assessment of Neuropsychological Status
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defining the transient and persistent groups. Gait velocity in
the elderly represents a final pathway combining balance,
motor, sensory systems, as well as cognition [30]. In
addition, the fact that gait velocity predicted persistent
MPS is supported by recent findings in non-demented older
adults without idiopathic PD: bradykinesia that represents a
required feature for parkinsonism has been associated with
gait velocity [21]. From a metabolic perspective, gait speed
was associated with cholinergic but not dopaminergic
denervation in PD patients; [31] suggesting a close rela-
tionship between gait and the cholinergic system. No other
suspected risk factors than gait speed predicted the per-
sistence of MPS.
In a similar longitudinal aging study investigating MPS
and other predictors of dementia, Louis et al. [12]
revealed that only MPS predicted dementia, but did not
find an interaction with other known risk factors for
dementia, including vascular risk factors or APOE-e4
positive status. Although previous studies have shown that
the presence of MPS in non-demented older adults pre-
dicted incident dementia [6, 7, 12], cognitive function did
not predict the stability nor the appearance of MPS in the
present study. This could be explained by the fact that our
definition of MPS purposefully did not include the pos-
tural instability and gait disturbance (PIGD) items from
the UPDRS that were the main contributing factor for
incident dementia in the religious order study [6]. Finally,
the number of included participants in the present study is
likely not large enough to show such a prediction. Taken
together, the absence of vascular risk factors as predictors
of persistent MPS and the progression of declines in gait
velocity could suggest the contribution of underlying
neurodegenerative processes, like PD, AD, or other non-
vascular parkinsonian syndromes in the persistent MPS
group.
The clinical profile of the MPS between the persistent
and transient groups was different. Although rigidity was
present in 83 % of participants in both groups, bradyki-
nesia was the discriminative feature between the two
groups, with the highest prevalence in the persistent group.
Interestingly, in a study examining the association of MPS
and white matter disease in the elderly, bradykinesia was
independently related with the presence of the lacunar
infarcts [32]. Regarding the complex link between MPS
and cerebrovascular disease, the presence of cerebrovas-
cular disease did not predict the stability or onset of new
MPS, whereas cardiovascular disease did predict the new
onset of MPS. Cardiovascular conditions, like atrial
fibrillation, precede cerebrovascular conditions and con-
stitute very well known risk factors for cerebrovascular
conditions [33]. This chronological sequence could explain
why cardiovascular but not cerebrovascular diseases
predict MPS. An alternative explanation could refer to the
fact that cardiovascular diseases outweigh cerebrovascular
diseases. Regarding the pathophysiology of vascular par-
kinsonism and its high prevalence in older adults [34], it is
likely that vascular mechanisms are key contributors to the
appearance of MPS in aging.
As a limitation, the short follow-up period and the rel-
ative small sample size, especially in the transient MPS
group, could mask some additional predictors, like cogni-
tive functions. These results should be replicated in a larger
prospective cohort with longer follow-up intervals. In
addition to the good internal consistency and inter-rater
reliability of MPS in this study, the differences observed at
baseline between the transient and persistent MPS groups
(i.e. slower gait velocity in the persistent group compared
to the transient group); the fact that applying more stringent
criteria does not modify the results; and the fact that gait
velocity decreases in the persistent group and increases in
the transient group all suggest that our findings are con-
sistent and not due to a reliability issue.
In conclusion, we observed that MPS may be reversible
in the elderly and that gait velocity predicts the progression
of MPS. Regarding new onset of MPS in aging, cardio-
vascular disease constitutes the main predictor. Our results
suggest vascular mechanisms as the trigger of MPS in
aging that are potentially reversible. However, for the
progression of MPS, additional investigations are required
to determine the pathophysiological mechanisms, possibly
neurodegenerative, underlying gait velocity.
Highlights
1) MPS can be reversible in healthy older adults.
2) Slow gait velocity was the main predictor of persistent
MPS in normal aging.
3) Cardiovascular disease was associated with onset of
new MPS.
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